| Nome |
# |
|
Allergen Immunotherapy: History and Future Developments, file e268c4ca-e002-a6b7-e053-3a05fe0adea1
|
277
|
|
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation, file e268c4ca-a76d-a6b7-e053-3a05fe0adea1
|
247
|
|
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19, file d85263f2-9548-4fd3-882d-90fbcf198e12
|
191
|
|
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma?, file e268c4ca-aac0-a6b7-e053-3a05fe0adea1
|
187
|
|
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients, file e268c4ca-aad0-a6b7-e053-3a05fe0adea1
|
160
|
|
Local Side Effects of Sublingual and Oral Immunotherapy, file e268c4ca-e000-a6b7-e053-3a05fe0adea1
|
155
|
|
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma, file e268c4ca-b837-a6b7-e053-3a05fe0adea1
|
128
|
|
Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region, file e268c4ca-dc3a-a6b7-e053-3a05fe0adea1
|
114
|
|
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials, file e268c4ca-d88d-a6b7-e053-3a05fe0adea1
|
112
|
|
The patient with rhinitis in the pharmacy. A cross-sectional study in real life, file e268c4ca-cd4b-a6b7-e053-3a05fe0adea1
|
75
|
|
Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study, file e268c4ca-b251-a6b7-e053-3a05fe0adea1
|
70
|
|
The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners, file e268c4ca-b970-a6b7-e053-3a05fe0adea1
|
68
|
|
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN), file e268c4ca-fb38-a6b7-e053-3a05fe0adea1
|
68
|
|
Galectin-3: An early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months, file e268c4ca-9fa0-a6b7-e053-3a05fe0adea1
|
65
|
|
Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement, file e268c4ca-d4e6-a6b7-e053-3a05fe0adea1
|
65
|
|
The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial, file e268c4c6-b786-a6b7-e053-3a05fe0adea1
|
64
|
|
Work productivity in rhinitis using cell phones: The MASK pilot study, file e268c4ca-c7ee-a6b7-e053-3a05fe0adea1
|
64
|
|
The perception of allergen-specific immunotherapy among pediatricians in the primary care setting, file e268c4cb-73d0-a6b7-e053-3a05fe0adea1
|
62
|
|
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience, file e268c4ca-a76b-a6b7-e053-3a05fe0adea1
|
60
|
|
Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA, file e268c4ca-d5cb-a6b7-e053-3a05fe0adea1
|
60
|
|
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle, file e268c4ca-cb56-a6b7-e053-3a05fe0adea1
|
58
|
|
Personalized medicine in allergy, file e268c4ca-b41a-a6b7-e053-3a05fe0adea1
|
56
|
|
Pidotimod: The state of art, file e268c4ca-b975-a6b7-e053-3a05fe0adea1
|
56
|
|
Allergen immunotherapy on the way to product-based evaluation - a WAO statement, file e268c4ca-c4f3-a6b7-e053-3a05fe0adea1
|
56
|
|
Why a registry of Chronic Urticaria (CUR) is needed, file e268c4ca-a994-a6b7-e053-3a05fe0adea1
|
55
|
|
The WEB-based Asthma Control: An intriguing connection or a dangerous hazard?, file e268c4ca-cdca-a6b7-e053-3a05fe0adea1
|
55
|
|
Psychological aspects in asthma: Do psychological factors affect asthma management?, file e268c4ca-d45f-a6b7-e053-3a05fe0adea1
|
54
|
|
Local allergic rhinitis: Entopy or spontaneous response?, file e268c4ca-e1be-a6b7-e053-3a05fe0adea1
|
54
|
|
Allergic diseases in the elderly: Biological characteristics and main immunological and non-immunological mechanisms, file e268c4ca-b415-a6b7-e053-3a05fe0adea1
|
53
|
|
Appropriateness in allergic respiratory diseases health care in Italy: Definitions and organizational aspects, file e268c4ca-d4e0-a6b7-e053-3a05fe0adea1
|
52
|
|
Therapeutic interventions in severe asthma, file e268c4ca-d4f7-a6b7-e053-3a05fe0adea1
|
52
|
|
Biomarker discovery in asthma and COPD by proteomic approaches, file e268c4c6-b570-a6b7-e053-3a05fe0adea1
|
50
|
|
Biomarkers and severe asthma: a critical appraisal., file e268c4ca-d6cc-a6b7-e053-3a05fe0adea1
|
48
|
|
Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?, file e268c4ca-b41f-a6b7-e053-3a05fe0adea1
|
47
|
|
Catching allergy by a simple questionnaire, file e268c4ca-e3db-a6b7-e053-3a05fe0adea1
|
43
|
|
Beta₂-agonists for exercise-induced asthma., file e268c4c6-dbea-a6b7-e053-3a05fe0adea1
|
41
|
|
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language., file e268c4c6-bb91-a6b7-e053-3a05fe0adea1
|
24
|
|
Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial, file e268c4c6-c116-a6b7-e053-3a05fe0adea1
|
23
|
|
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020), file e268c4cd-8948-a6b7-e053-3a05fe0adea1
|
19
|
|
ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy, file e268c4ce-7a07-a6b7-e053-3a05fe0adea1
|
17
|
|
Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model, file e268c4cd-4b8b-a6b7-e053-3a05fe0adea1
|
16
|
|
Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis., file e268c4c6-b6f3-a6b7-e053-3a05fe0adea1
|
14
|
|
30 Years Of Sublingual Immunotherapy, file e268c4cb-a6aa-a6b7-e053-3a05fe0adea1
|
13
|
|
Is diet partly responsible for differences in COVID-19 death rates between and within countries?, file e268c4cd-3e2f-a6b7-e053-3a05fe0adea1
|
12
|
|
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life, file e268c4cd-448a-a6b7-e053-3a05fe0adea1
|
12
|
|
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments, file b32882f5-b11f-4739-891f-22dc8680c057
|
10
|
|
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19, file e268c4cc-cdbb-a6b7-e053-3a05fe0adea1
|
10
|
|
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0), file e268c4ce-60ab-a6b7-e053-3a05fe0adea1
|
7
|
|
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone, file e268c4c7-0cb1-a6b7-e053-3a05fe0adea1
|
6
|
|
null, file e268c4cd-08bd-a6b7-e053-3a05fe0adea1
|
6
|
|
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App, file e268c4cc-e48e-a6b7-e053-3a05fe0adea1
|
5
|
|
COVID-19, asthma, and biological therapies: What we need to know, file e268c4cd-61a7-a6b7-e053-3a05fe0adea1
|
5
|
|
Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients., file e268c4c6-c2a0-a6b7-e053-3a05fe0adea1
|
4
|
|
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum ctla-4 and IL-10., file e268c4c6-b78f-a6b7-e053-3a05fe0adea1
|
3
|
|
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies, file e268c4c8-85e3-a6b7-e053-3a05fe0adea1
|
3
|
|
Umeclidinium for the treatment of uncontrolled asthma, file e268c4ca-be5b-a6b7-e053-3a05fe0adea1
|
3
|
|
Biosimilars in allergic diseases, file e268c4ca-f702-a6b7-e053-3a05fe0adea1
|
3
|
|
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies, file 5863516d-ea73-4e4b-a554-9c9ddd692662
|
2
|
|
Evaluation of asthma control in the pharmacy: An italian cross-sectional study, file e268c4ca-8bbb-a6b7-e053-3a05fe0adea1
|
2
|
|
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis, file e268c4ca-a909-a6b7-e053-3a05fe0adea1
|
2
|
|
Do Asthmatic Patients and Their Physicians Agree on the Presence and Severity of Allergic Rhinitis?, file e268c4ca-b972-a6b7-e053-3a05fe0adea1
|
2
|
|
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases, file e268c4ca-bc18-a6b7-e053-3a05fe0adea1
|
2
|
|
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma, file e268c4ca-c1e6-a6b7-e053-3a05fe0adea1
|
2
|
|
Update on immunotherapy for the treatment of asthma, file e268c4ca-d119-a6b7-e053-3a05fe0adea1
|
2
|
|
Latex allergy and occupational exposure: The patient’s perspective, file e268c4ca-fe9c-a6b7-e053-3a05fe0adea1
|
2
|
|
Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document, file e268c4ce-878e-a6b7-e053-3a05fe0adea1
|
2
|
|
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps, file 273d79ee-7979-45d3-b592-ebf394755e15
|
1
|
|
The cross-cultural validation of the English version of RhinAsthma patient's perspective (RAPP), file e268c4ca-46c9-a6b7-e053-3a05fe0adea1
|
1
|
|
CD4+CD25highCD127- regulatory T-cells in COPD: Smoke and drugs effect, file e268c4ca-4ad0-a6b7-e053-3a05fe0adea1
|
1
|
|
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice, file e268c4ca-4e8a-a6b7-e053-3a05fe0adea1
|
1
|
|
Molecular diagnosis and precision medicine in allergy management, file e268c4ca-9048-a6b7-e053-3a05fe0adea1
|
1
|
|
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life, file e268c4ca-9a50-a6b7-e053-3a05fe0adea1
|
1
|
|
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma, file e268c4ca-a767-a6b7-e053-3a05fe0adea1
|
1
|
|
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation), file e268c4ca-ab8f-a6b7-e053-3a05fe0adea1
|
1
|
|
Patient-reported outcomes in asthma clinical trials, file e268c4ca-ad5f-a6b7-e053-3a05fe0adea1
|
1
|
|
Genuair® Usability Test: Results of a National Public Survey of the Elderly, file e268c4ca-ae85-a6b7-e053-3a05fe0adea1
|
1
|
|
Vitamin D levels and allergic diseases. An italian cross-sectional multicenter survey, file e268c4ca-b007-a6b7-e053-3a05fe0adea1
|
1
|
|
Allergen immunotherapy as add-on to biologic agents, file e268c4ca-b5ed-a6b7-e053-3a05fe0adea1
|
1
|
|
Choosing wisely: Practical considerations on treatment efficacy and safety of asthma in the elderly, file e268c4ca-b7b2-a6b7-e053-3a05fe0adea1
|
1
|
|
Quality-of-life issues in survivors to anaphylactic reactions to drugs, file e268c4ca-bc20-a6b7-e053-3a05fe0adea1
|
1
|
|
Asthma management in a specialist setting: Results of an Italian Respiratory Society survey, file e268c4ca-be51-a6b7-e053-3a05fe0adea1
|
1
|
|
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation, file e268c4ca-bf80-a6b7-e053-3a05fe0adea1
|
1
|
|
Switching treatments in COPD: Implications for costs and treatment adherence, file e268c4ca-cb5d-a6b7-e053-3a05fe0adea1
|
1
|
|
Public awareness on cystic fibrosis: Results from a national pragmatic survey, file e268c4ca-cf8b-a6b7-e053-3a05fe0adea1
|
1
|
|
Disability in moderate chronic obstructive pulmonary disease: Prevalence, burden and assessment-results from a real-life study, file e268c4ca-cf8f-a6b7-e053-3a05fe0adea1
|
1
|
|
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology, file e268c4ca-da46-a6b7-e053-3a05fe0adea1
|
1
|
|
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation, file e268c4ca-da59-a6b7-e053-3a05fe0adea1
|
1
|
|
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma, file e268c4ca-e008-a6b7-e053-3a05fe0adea1
|
1
|
|
Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey, file e268c4ca-e37e-a6b7-e053-3a05fe0adea1
|
1
|
|
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9), file e268c4ca-f400-a6b7-e053-3a05fe0adea1
|
1
|
|
The path to personalized medicine in asthma, file e268c4cb-fa23-a6b7-e053-3a05fe0adea1
|
1
|
|
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation, file e268c4cc-967f-a6b7-e053-3a05fe0adea1
|
1
|
|
Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy, file e268c4cd-5aa2-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
3.382 |